Carboplatin plus nab-paclitaxel in performance status 2 patients with advanced non-small-cell lung cancer

Abstract

Background/Aim: This phase I/II study aimed at assessing the efficacy of combination therapy with carboplatin (CBDCA) on day 1 and nab-paclitaxel (Nab-PTX) on days 1 and 8 of a 21-day cycle in performance status (PS) 2 patients with non-small-cell lung cancer (NSCLC). Patients and Methods: PS 2 patients with NSCLC were enrolled into a phase I study using a 3 + 3 design. Once the recommended phase II dose (RP2D) was established, the patients were enrolled into phase II. Results: Based on the phase I findings, the RP2D was determined as CBDCA area under the curve 6 mg/ml/min and Nab-PTX 100 mg/m 2 . In the phase II part, 27 patients were evaluable. The overall response rate was 44%. The median progression-free survival and overall survival were 5.2 months and 14.0 months, respectively. There was no treatment-related death. Conclusion: CBDCA plus Nab-PTX therapy is a promising treatment strategy for PS 2 patients with NSCLC.